Navigation Links
New Mesothelioma Treatment Shows Promise
Date:3/22/2010

Non-toxic vaccine clinical trial, funded by the Mesothelioma Applied Research Foundation, publishes successful results for mesothelioma treatment.

(PRWEB) March 22, 2010 -- A new dendritic cell-based immunotherapy has been demonstrated in clinical trial to be well-tolerated and capable of inducing an immunological response against mesothelioma cells in patients.

In the study, funded by the Mesothelioma Applied Research Foundation and just published in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine, researchers administered three vaccinations of clinical-grade autologous dendritic cells to ten pleural mesothelioma patients. Distinct immunological responses, with moderate fever as the only side-effect, and with no evidence of autoimmunity or severe toxicities, mark an important milestone in mesothelioma research.

“For the past several years, aggressive chemotherapy has been utilized as an often effective, but difficult-to-tolerate, drug regimen for mesothelioma treatment. The prospect of adding to our arsenal other effective, but less toxic and better-tolerated, treatments will broaden greatly our ability to treat patients,” says Mary Hesdorffer, NP, Medical Liaison for the Mesothelioma Applied Research Foundation.

Joachim G. Aerts, a co-author of the research study and pulmonary physician at Erasmus Medical Center in the Netherlands, says: “We hope that by further development of our method it will be possible to increase survival in patients with mesothelioma and eventually vaccinate persons who have been in contact with asbestos to prevent them from getting asbestos-related diseases.”

Mesothelioma is a malignant tumor of the lining of the lung, abdomen or heart caused by asbestos. Medical experts consider it one of the most aggressive of all cancers. For decades it was regarded as untreatable, deadly and hopeless; and so, in a sad, self-fulfilling prophecy, the need for research to develop effective treatments was mostly ignored. For the Mesothelioma Applied Research Foundation and today’s patients, their families, and the millions of Americans who in the last five decades have been exposed to asbestos and are at risk for the cancer, this is unacceptable.

The Mesothelioma Applied Research Foundation is the national non-profit dedicated to finding a cure for mesothelioma by funding research, providing education and support for patients, and leading advocacy efforts for a national commitment to end the mesothelioma tragedy. The Foundation hosts the annual International Symposium on Malignant Mesothelioma, which unites doctors, researchers, patients and families, legal advocates, union representatives and other concerned individuals to share information and advance mesothelioma research. For more information visit www.curemeso.org.

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3758744.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Mesocare.org Presents “Ask the Expert” for Mesothelioma Patients and Their Families
2. Sokolove Law's MesoRC Site Serves Illinois Mesothelioma Patients and their Families
3. Attorney Joe Belluck Hails Department Of Defense For Increased Funding Of Mesothelioma Research
4. Advancing Mesothelioma Research
5. Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options
6. Possible vaccine for mesothelioma proven safe
7. U.K.: Justice for Asbestos Disease Victims Requires Mesothelioma Research Funding
8. National Asbestos Lawyers of Cooney Conway Launches Mesothelioma Portal
9. Steroids May Be Overrated in Treatment of COPD
10. Experimental stem cell treatment arrests acute lung injury in mice, study shows
11. Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Mesothelioma Treatment Shows Promise 
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve their approach ... patient is doing more than filling out a survey; in many cases health professionals ... emphasis in health care and research on the importance of active engagement with patients ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology: